TY - JOUR AU - Packer, Milton AU - Anker, Stefan D. AU - Butler, Javed AU - Filippatos, Gerasimos AU - Pocock, Stuart J. AU - Carson, Peter AU - Januzzi, James AU - Verma, Subodh AU - Tsutsui, Hiroyuki AU - Brueckmann, Martina AU - Jamal, Waheed AU - Kimura, Karen AU - Schnee, Janet AU - Zeller, Cordula AU - Cotton, Daniel AU - Bocchi, Edimar AU - Böhm, Michael AU - Choi, Dong-Ju AU - Chopra, Vijay AU - Chuquiure, Eduardo AU - Giannetti, Nadia AU - Janssens, Stefan AU - Zhang, Jian AU - Gonzalez Juanatey, Jose R. AU - Kaul, Sanjay AU - Brunner-La Rocca, Hans-Peter AU - Merkely, Béla Péter AU - Nicholls, Stephen J. AU - Perrone, Sergio AU - Pina, Ileana AU - Ponikowski, Piotr AU - Sattar, Naveed AU - Senni, Michele AU - Seronde, Marie-France AU - Spinar, Jindrich AU - Squire, Iain AU - Taddei, Stefano AU - Wanner, Christoph AU - Zannad, Faiez TI - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 383 PY - 2020 IS - 15 SP - 1413 EP - 1424 PG - 12 SN - 0028-4793 DO - 10.1056/NEJMoa2022190 UR - https://m2.mtmt.hu/api/publication/31591917 ID - 31591917 N1 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't LA - English DB - MTMT ER - TY - JOUR AU - McMurray, John J V AU - Solomon, Scott D AU - Inzucchi, Silvio E AU - Køber, Lars AU - Kosiborod, Mikhail N AU - Martinez, Felipe A AU - Ponikowski, Piotr AU - Sabatine, Marc S AU - Anand, Inder S AU - Bělohlávek, Jan AU - Böhm, Michael AU - Chiang, Chern-En AU - Chopra, Vijay K AU - de Boer, Rudolf A AU - Desai, Akshay S AU - Diez, Mirta AU - Drozdz, Jaroslaw AU - Dukát, Andrej AU - Ge, Junbo AU - Howlett, Jonathan G AU - Katova, Tzvetana AU - Kitakaze, Masafumi AU - Ljungman, Charlotta E A AU - Merkely, Béla Péter AU - Nicolau, Jose C AU - O'Meara, Eileen AU - Petrie, Mark C AU - Vinh, Pham N AU - Schou, Morten AU - Tereshchenko, Sergey AU - Verma, Subodh AU - Held, Claes AU - DeMets, David L AU - Docherty, Kieran F AU - Jhund, Pardeep S AU - Bengtsson, Olof AU - Sjöstrand, Mikaela AU - Langkilde, Anna-Maria ED - Masszi, Gabriella / Collaborator TI - Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. JF - NEW ENGLAND JOURNAL OF MEDICINE J2 - NEW ENGL J MED VL - 381 PY - 2019 IS - 21 SP - 1995 EP - 2008 PG - 14 SN - 0028-4793 DO - 10.1056/NEJMoa1911303 UR - https://m2.mtmt.hu/api/publication/30828891 ID - 30828891 N1 - BHF Cardiovascular Research Centre, University of Glasgow, 126 University Pl., Glasgow, G128TA, United Kingdom Cardiovascular Division, TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, United States Section of Endocrinology, Yale University School of Medicine, New Haven, CT, United States Rigshospitalet Copenhagen University Hospital, Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark Department of Medicine, Saarland University Hospital, Homburg-Saar, Germany Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City, United States National University of Cordoba, Cordoba, Spain Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina Wroclaw Medical University, Wroclaw, Poland Department of Cardiology, Medical University of Lodz, Lodz, Poland Department of Cardiology, University of Minnesota, Minneapolis, United States 2nd Department of Internal Medicine, Department of Cardiovascular Medicine, General Teaching Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic Division of Cardiology, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan Department of Cardiology, Medanta, Gurgaon, India Department of Cardiology, University Medical Center, University of Groningen, Groningen, Netherlands 5th Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada Department of Cardiology, Montreal Heart Institute, Montreal, Canada Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan Department of Molecular and Clinical Medicine and Cardiology, Sahlgrenska Academy, AstraZeneca, Gothenburg, Sweden Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden Heart and Vascular Center, Semmelweis University, Budapest, Hungary Instituto Do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Saõ Paolo, Saõ Paolo, Brazil Department of Internal Medicine, Tan Tao University, Tan Duc, Viet Nam Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russian Federation Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, United States Division of Cardiac Surgery, St. Michael's Hospital, University of Toronto, Toronto, Canada Cited By :1420 Export Date: 6 October 2021 CODEN: NEJMA Correspondence Address: McMurray, J.J.V.; BHF Cardiovascular Research Centre, 126 University Pl., United Kingdom; email: john.mcmurray@glasgow.ac.uk Chemicals/CAS: dapagliflozin, 461432-26-8; digitalis, 8031-42-3, 8053-83-6; sacubitril plus valsartan, 936623-90-4; glucoside, 50986-29-3; glycosylated hemoglobin, 9062-63-9; 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; Benzhydryl Compounds; Cardiovascular Agents; Glucosides; Glycated Hemoglobin A; Sodium-Glucose Transporter 2 Inhibitors AB - In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups.Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.). LA - English DB - MTMT ER -